Clinical trial
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
NCT00064090 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00064090 |
|---|---|
| Title | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer |
| Official title | A Phase I Study of Triapine and Cytarabine in Patients With Hematologic Malignancies |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Drug |
| Interventions | cytarabine, triapine |
| Start date | Mar 1, 2003 |
| Primary completion | Sep 1, 2004 |
| Completion | Jan 1, 2008 |
| First posted | Jul 9, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: